INTS: רווח נקי למניה (EPS TTM) Intensity Tx
The TTM net income per share distribution for Intensity Therapeutics (INTS) visualizes a monetization strategy centered on intratumoral drugs against metastases. The current value is -4.36, highlighting a reliance on venture capital infusions in the absence of stable cash flow. A team of leading oncologists, attracted by the innovative treatment approach, is spearheading the development. This indicator smooths the time lags between corporate news and the market price.
פילוחי נתונים אנליטיים מרוכזים עבור Intensity Therapeutics Inc (INTS)
This indicator is calculated by dividing total annual net income by the total number of shares outstanding. The metric reflects the actual efficiency of profit generation per share, neutralizing the impact of issuance. For Intensity Therapeutics (INTS), this calculation highlights the capital's dependence on the success of a single oncology drug. Binary clinical trial risks make profit dynamics extremely volatile. By analyzing this 12-month net income per share chart, an investor assesses the degree of business scalability.
